Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBF 1120 phase 3 placebo-controlled trial in idiopathic pulmonary fibrosis
NL-OMON37976Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing BIBF 1120 with Placebo (2 arms). Primary endpoint: Annual rate of decline in forced vital capacity. Started Jul 2011; status: active, not recruiting.
02
Drugs
nintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON37976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37976.